OncoMatch/Clinical Trials/NCT05398302
Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy
Is NCT05398302 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for castration-resistant prostate carcinoma.
This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Required: Stage IV, IVA, IVB
Metastatic disease required
Prior therapy
Must have received: radioiodine (177Lu-PSMA-617) — expanded access protocol or approved trial
Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial
Lab requirements
Blood counts
Platelets > 75,000/ul within 14 days prior to biopsy; PT or INR and PTT < 1.5x ULN within 14 days prior to biopsy
Platelets > 75,000/ul within 14 days prior to biopsy; PT or INR and PTT < 1.5 times the institutional upper limit normal (ULN) within 14 days prior to biopsy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA / Jonsson Comprehensive Cancer Center · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify